Indications for Aortic Valve Replacement and TAVI
Surgical Aortic Valve Replacement (SAVR) Indications
SAVR is the preferred intervention for symptomatic severe aortic stenosis in younger patients (<65 years), those with life expectancy >20 years, and low surgical risk patients 1, 2.
Class I Indications (Strongest Evidence):
- Symptomatic severe AS (any symptoms: dyspnea, angina, syncope) 3, 1, 3
- Severe AS undergoing CABG, ascending aortic surgery, or other valve surgery 3, 1, 3
- Asymptomatic severe AS with LVEF <50% (when not due to other causes) 1
- Asymptomatic severe AS with abnormal exercise test showing symptoms during exercise 1
Class IIa Indications (Should Be Considered):
- Symptomatic moderate AS undergoing CABG or other cardiac surgery 3, 1, 3
- Asymptomatic severe AS with abnormal exercise test showing fall in blood pressure below baseline 1
- Asymptomatic severe AS with very severe hemodynamics (peak velocity >5.5 m/s OR severe valve calcification with rapid progression ≥0.3 m/s per year) in low surgical risk patients 1
- Symptomatic low-flow, low-gradient AS with reduced EF and evidence of flow reserve 1
Class IIb Indications (May Be Considered):
- Asymptomatic extremely severe AS (AVA ≤0.6 cm², mean gradient ≥60 mmHg, or jet velocity ≥5 m/s) 3
- Asymptomatic severe AS with excessive LV hypertrophy without hypertension 1
- Symptomatic low-flow, low-gradient AS with LV dysfunction without flow reserve 1
Transcatheter Aortic Valve Implantation (TAVI) Indications
TAVI is recommended for symptomatic severe AS in patients ≥80 years, those with prohibitive or high surgical risk, and increasingly for intermediate-risk patients aged 65-80 years with suitable anatomy 3, 1, 2, 3.
Primary TAVI Indications:
Prohibitive Surgical Risk:
- ≥50% estimated risk of mortality or irreversible morbidity at 30 days 3
- Specific prohibitive factors: frailty, prior chest radiation, porcelain aorta, severe hepatic or pulmonary disease 3
- Predicted survival >12 months 3, 1, 3
High Surgical Risk:
- STS score ≥8% or equivalent high-risk profile 3, 2, 3
- Multiple comorbidities: oxygen-dependent lung disease, dialysis, cirrhosis with MELD >14 2
Age-Based Recommendations:
- Age ≥80 years: TAVI preferred over SAVR (Class IA) 2
- Age 65-80 years: Either TAVI or SAVR reasonable after shared decision-making regarding valve durability vs. life expectancy 2
- Age <65 years: SAVR strongly preferred due to concerns about long-term valve durability 1, 2
Anatomical Requirements for TAVI:
- Suitable transfemoral access (vessel size, minimal calcification, acceptable tortuosity) 1
- Appropriate annulus size (18-29 mm with current devices) 1
- Trileaflet calcific aortic valve 3
Absolute Contraindications to TAVI
TAVI should not be performed when: 1
- Life expectancy <1 year from comorbidities
- No cardiac surgery on-site or absence of Heart Team
- Active endocarditis
- LV thrombus
- Inadequate annulus size (<18 mm or >29 mm)
- High risk of coronary obstruction (asymmetric calcification, short annulus-to-coronary distance, small sinuses)
- Mobile thrombi in ascending aorta or arch
- Severe other valve disease requiring surgery that contributes to symptoms
- Inadequate vascular access for transfemoral approach without alternative access
Decision Algorithm: SAVR vs. TAVI
Step 1: Confirm Severe Symptomatic AS
- Symptoms present (dyspnea, angina, syncope) with severe AS confirmed by echo
Step 2: Age Assessment
- <65 years: SAVR preferred 2
- 65-80 years: Either approach reasonable; consider life expectancy vs. valve durability 2
- ≥80 years: TAVI preferred 2
Step 3: Surgical Risk Stratification
- Low risk (STS <4%): SAVR preferred in younger patients 2
- Intermediate risk (STS 4-8%): Either approach; favor TAVI if age ≥75 2
- High risk (STS ≥8%): TAVI preferred 3, 2, 3
- Prohibitive risk (≥50% mortality): TAVI only option 3
Step 4: Anatomical Assessment
- TAVI-favorable anatomy: Suitable femoral access, appropriate annulus, trileaflet valve → proceed with TAVI if age/risk appropriate
- TAVI-unfavorable anatomy: Porcelain aorta, hostile chest, small annulus (<21 mm) → may favor TAVI despite anatomy 2
- SAVR-favorable anatomy: Bicuspid valve, need for other cardiac surgery → favor SAVR 1, 2
Step 5: Patient-Specific Factors
- Life expectancy >20 years: SAVR strongly preferred due to durability concerns 2
- Life expectancy 10-20 years: Shared decision-making required 2
- Life expectancy <10 years: TAVI preferred if anatomically suitable 2
Critical Pitfalls to Avoid
Do not perform TAVI in patients <65 years with low surgical risk unless exceptional circumstances exist—recent data show worse 5-year survival compared to SAVR in this population 4.
Do not delay intervention in symptomatic severe AS—mortality without treatment is 50% at 2 years 3.
Do not use TAVI as first-line in patients requiring concomitant cardiac procedures (CABG, other valve surgery, ascending aortic surgery)—these patients need SAVR 1, 2.
Recognize that bicuspid valves and non-calcified valves are relative contraindications to TAVI 1.
Heart Team evaluation is mandatory—this is not optional and should include cardiac surgery, interventional cardiology, imaging specialists, and consideration of patient values 3, 1, 3, 5.
Special Populations
Low-Flow, Low-Gradient AS:
- Confirm true severe AS with dobutamine stress echo or CT calcium scoring
- If flow reserve present: AVR recommended (SAVR or TAVI based on risk/age) 1
- If no flow reserve: AVR may still benefit but higher operative mortality 1
Asymptomatic Severe AS:
- SAVR (not TAVI) if LVEF <50%, abnormal exercise test, or very severe hemodynamics in low-risk patients 1, 6
- Close surveillance every 6 months if none of above criteria met 1
Balloon Aortic Valvuloplasty: